Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

STD prevention programs in schools: Mixed outcomes on sexual behaviors

Teaching teens about sexually transmitted infections at school boosts factual knowledge, but does not necessarily translate to increased condom use, according to a new review from the United Kingdom.

26 Feb 2010

Health Canada approves GARDASIL for prevention of genital warts in males

Today, Merck announced that Health Canada has approved GARDASIL(R) (Human Papillomavirus Quadrivalent (Types 6, 11, 16, and 18) Recombinant Vaccine) for boys and men nine through 26 years of age for the prevention of infection caused by HPV types 6, 11, 16, and 18 and genital warts caused by HPV types 6 and 11.

23 Feb 2010

HPV DNA testing vital in identification of cervical cancer

Roche Molecular Systems, Inc. announced today that preliminary data from its ATHENA (Addressing THE Need for Advanced HPV Diagnostics) trial support the importance of screening for human papillomavirus (HPV) genotypes that put women at highest risk for developing cervical cancer. ATHENA is a prospective, double-blind, multi-centered, 47,000-patient, U.S.-registration trial designed to demonstrate the effectiveness of HPV detection as part of a cervical cancer screening program.

18 Feb 2010

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Merck & Co., Inc. announced today that in new Phase III data, GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant] was 77.5 percent (95 percent CI: 39.6, 93.3) efficacious against anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men. The data were presented at the European Research Organization on Genital Infection and Neoplasia (EUROGIN) conference in Monte Carlo, Monaco.

18 Feb 2010

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

In a new phase III study, GARDASIL(R) (Quadrivalent Human Papillomavirus (Types 6, 11, 16 and 18) Recombinant Vaccine) prevented 77.5 per cent of anal intraepithelial neoplasia (AIN) associated with human papillomavirus (HPV) types 6, 11, 16 and 18 in 16-to-26 year-old men who have sex with men.

17 Feb 2010

Merck announces global sales of $27.4 billion for full-year 2009

Merck & Co., Inc. today announced financial results for the fourth quarter and the full year of 2009 which include the results of legacy Schering-Plough operations from the close of the merger on Nov. 3, 2009 through Dec. 31, 2009.

16 Feb 2010

Overall benefits of HPV vaccination or frequent screening are low for women over 41

The overall potential benefits of human papillomavirus (HPV) vaccinations or frequent HPV screenings for women over the age of 41 are low, concludes a new study published online February 15 in the Journal of the National Cancer Institute. The study found that the rate of new infections preventable by vaccination declines with age. Furthermore, new infections among women at any age typically do not progress to cervical intraepithelial neoplasia grade 2 (CIN 2) or CIN 3, the precursors for cervical cancer.

16 Feb 2010

Public health researchers at UNC to lead multi-state initiative to prevent cervical cancer

Asserting that no one should die from cervical cancer, public health researchers at the University of North Carolina at Chapel Hill are leading a multi-state initiative to prevent - or even eradicate - the disease.

16 Feb 2010

Tobacco users with HPV-positive head and neck cancers at increased risk of recurrence

Patients with head and neck cancer linked to high risk human papillomavirus, or HPV, have worse outcomes if they are current or former tobacco users, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center.

15 Feb 2010

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Commenting on the Group's 2009 performance, sanofi-aventis Chief Executive Officer Christopher A. Viehbacher said, "2009 was the first year of implementation of our new strategy. Major steps have already been achieved in strengthening our growth platforms and reinforcing our R&D pipeline while delivering a double-digit EPS(1) growth".

10 Feb 2010

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

Inovio Biomedical Corporation, a leader in DNA vaccine design, development and delivery, announced today additional interim safety and immunogenicity data from its therapeutic cervical cancer vaccine (VGX-3100) trial. VGX-3100 is a DNA vaccine targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 and 18 and is delivered via in vivo electroporation.

8 Feb 2010

HPV vaccination programs may reduce genital diseases

High-coverage human papillomavirus (HPV) vaccinations among adolescents and young women may result in a rapid reduction of genital warts, cervical cell abnormalities, and diagnostic and therapeutic procedures, researchers report in a new study published online February 5 in the Journal of the National Cancer Institute. Some of these genital abnormalities are precursors of cervical, vulvar, and vaginal cancers.

6 Feb 2010

New report finds low adult vaccination rates in U.S.

A new report, Adult Immunization: Shots to Save Lives, released today by the Trust for America's Health (TFAH), the Infectious Diseases Society of America (IDSA), and the Robert Wood Johnson Foundation (RWJF) found that more than 30 percent of adults ages 65 and older had not been immunized against pneumonia in 36 states as of 2008.

5 Feb 2010

Global cancer rates could be reduced by 40% with prevention strategies, report says

"Forty percent of the 12 million people diagnosed with cancer worldwide each year could avert the killer disease by protecting themselves against infections and changing their lifestyles, experts said on Tuesday," Reuters reports.

4 Feb 2010

Experimental vaccine protects mice and monkeys against chikungunya virus

An experimental vaccine developed using non-infectious virus-like particles (VLP) has protected macaques and mice against chikungunya virus, a mosquito-borne pathogen that has infected millions of people in Africa and Asia and causes debilitating pain, researchers at the National Institutes of Health have found.

29 Jan 2010

Texas to invest $4.5 mn in cancer research at UT Health Science Center

Texas plans to invest $3 billion in cancer research over the next 10 years and six scientists at The University of Texas Health Science Center at Houston are among the first to receive grants.The researchers, whose grants total $4.5 million, are working to protect girls from cervical cancer, to interrupt tumor growth at the molecular level and to develop a new approach for the treatment of colon cancer, among other cutting-edge projects.

27 Jan 2010

HPV testing could be used as standard method of cervical screening for women, say Italian scientists

Human papillomavirus (HPV) testing could be used as the standard method of cervical screening for women aged 35 years or older, as it seems to prevent more invasive cases of the disease than cytology screening alone, Italian scientists have said.

20 Jan 2010

Testing for high-risk types of HPV DNA can be effective in preventing invasive cervical cancer

Results from a study of more than 90,000 Italian women published by the Lancet Oncology found that testing for high-risk types of the human papillomavirus (HPV) DNA is significantly more effective in preventing invasive cervical cancer than cytology (Pap testing) alone.

19 Jan 2010

Study finds large number of new couples among young adults infected with HPV

A groundbreaking study of couples led by Professor Eduardo Franco, Director of McGill University's Cancer Epidemiology Unit, in collaboration with a team of colleagues from McGill and Universit- de Montr-al/Centre Hospitalier de l'Universit- de Montr-al (CHUM), found more than half (56 per cent) of young adults in a new sexual relationship were infected with human papillomavirus (HPV).

18 Jan 2010

SIRIUS XM Radio to broadcast medical breakthroughs and milestones of the last ten years

SIRIUS XM Radio today announced that it will broadcast The Dean's List: A Decade in Medicine, an in-depth special exploring the medical breakthroughs and milestones of the last ten years hosted by Dr. Andrew Brotman, Vice Dean for Clinical Affairs, NYU Langone Medical Center, on Doctor Radio, SIRIUS XM's 24/7 health and medical channel.

9 Jan 2010

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

STD prevention programs in schools: Mixed outcomes on sexual behaviors

Health Canada approves GARDASIL for prevention of genital warts in males

HPV DNA testing vital in identification of cervical cancer

Phase III data reveals potential of Merck’s GARDASIL in preventing HPV and HPV-related cancers

Phase III study: GARDASIL prevents 77.5% of pre-cursor lesions to anal cancer

Merck announces global sales of $27.4 billion for full-year 2009

Overall benefits of HPV vaccination or frequent screening are low for women over 41

Public health researchers at UNC to lead multi-state initiative to prevent cervical cancer

Tobacco users with HPV-positive head and neck cancers at increased risk of recurrence

sanofi-aventis reports 2009 fourth-quarter and full-year net earnings

Inovio Biomedical announces additional immunogenicity data from therapeutic cervical cancer vaccine trial

HPV vaccination programs may reduce genital diseases

New report finds low adult vaccination rates in U.S.

Global cancer rates could be reduced by 40% with prevention strategies, report says

Experimental vaccine protects mice and monkeys against chikungunya virus

Texas to invest $4.5 mn in cancer research at UT Health Science Center

HPV testing could be used as standard method of cervical screening for women, say Italian scientists

Testing for high-risk types of HPV DNA can be effective in preventing invasive cervical cancer

Study finds large number of new couples among young adults infected with HPV

SIRIUS XM Radio to broadcast medical breakthroughs and milestones of the last ten years

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Human Papillomavirus (HPV) News and Research

Latest Human Papillomavirus (HPV) News and Research

Shaping the Future of Neuroscience: A Conversation with Atlas Antibodies on the MolBoolean™ and the Impact of SfN 2024

How the Arts Reshape Brain Function: Susan Magsamen on the Future of Neuroaesthetics

Inside the Alzheimer's Association: Dr. Heather Snyder on Driving Research and Collaboration

Newsletters you may be interested in